Table 2 Risk of metastasis and DSS according to molecular characteristics found in the primary tumors.

From: Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome

Characteristic

Metastasis development

Disease specific survival (DSS)

This study

TCGA-KICH

This study

TCGA-KICH

Univariate

Multivariatea

Univariate

Multivariate

Univariate

Multivariate

Univariate

Multivariate

OR (95% CI),

P

OR (95% CI),

P

OR (95% CI),

P

OR (95% CI),

P

HR (95% CI),

P

HR (95% CI),

P

HR (95% CI),

P

HR (95% CI),

P

Mutated gene

 TP53

3.6 (1.3–10.4),

0.018

3.6 (0.9–13.8),

0.065

2.6 (0.7–9.3),

0.15

1.0 (0.2–5.4),

0.97

0.8 (0.2–4.2),

0.81

1.4 (0.2–9.1),

0.72

6.6 (1.3–34.0),

0.025

3.7 (0.4–33.5),

0.24

  MTOR/TSC1/TSC2

1.4 (0.4–5.0),

0.62

1.6 (0.3–7.9),

0.56

12.9 (1.2–137),

0.034

145 (2.5–8491),

0.016

5.5 (1.2–24.7),

0.027

10.7 (1.2–92.2),

0.031

10.3 (2.0–54.8),

0.006

670 (0.7–603146),

0.060

  PTEN

3.9 (0.5–29.6),

0.19

1.1 (0.1–11),

0.94

3.0 (0.6–15.6),

0.19

2.5 (0.2–27),

0.44

2.6 (0.3–21.8),

0.38

1.0 (0.1–8.8),

0.99

3.0 (0.6–15.6),

0.18

0.87 (0.05–14.1),

0.92

  Telomere maintenanceb

3.1 (0.9–11.3),

0.084

3.7 (0.8–17.6),

0.10

4.9 (1.1–20.9),

0.033

7.1 (0.9–57.3),

0.065

1.5 (0.3–7.6),

0.62

1.6 (0.3–8.7),

0.62

4.2 (0.9–18.7),

0.062

9.8 (0.8–123.5),

0.077

  Complex I resp. chain

3e−9 (NPd),

0.999

9e−9 (NP),

0.998

3.5 (0.8–15.6),

0.11

5.3 (0.7–38.5),

0.099

0.04 (0–2630),

0.56

0 (NP),

0.99

2.5 (0.5–13.1),

0.27

1.3 (0.2–9.3),

0.82

Protein expressionc

  p53 (overexpression)

8.8 (1.6–48.2),

0.012

7.3 (0.9–55.9),

0.057

  

44.2 (NP) 0.66

143.5 (NP),

0.65

  

  pS6 (S235–S236)

1.1 (0.3–3.9),

0.89

0.6 (0.1–3.3),

0.51

0.6 (0.3–1.6),

0.34

0.7 (0.2–2.4),

0.59

1.5 (0.3–7.7),

0.60

5.8 (0.4–86.4),

0.20

1.3 (0.4–4.4),

0.65

0.6 (0.04–10.5),

0.75

  1. Associations with a P value < 0.05 are given in bold. Full details of the association analysis are provided in Supplementary Table 3.
  2. aThe analysis includes as covariates: tumor stage, age and gender.
  3. bTelomere maintenance-related genes include TERT promoter,
  4. ATRX and DAXX.
  5. cProtein expression in this study was assessed by IHC, in TCGA study RPPA values were used.
  6. dLarge confidence interval, not provided (NP).
Back to article page